Autor: |
McCarthy RL; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.; Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK., Schwartz J; Pachyonychia Congenita Project, Salt Lake City, UT, USA., Oldham J; Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK., Bodemer C; Reference Center for Genodermatoses (MAGEC), Department of Dermatology, APHP, Hôpital Necker-Enfants Malades, Paris, France., Greco C; Department of Pain and Palliative Care, Hôpital Necker-Enfants Malades, Paris, France.; ATIP/Avenir Team 'Targeted Pain Therapy and Drug Repurposing in Genetic Skin Diseases', U1163 INSERM, Imagine Institut, Paris, France., Hovnanian A; INSERM UMR 1163, Université Paris Cité, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France., Hansen CD; Pachyonychia Congenita Project, Salt Lake City, UT, USA.; Department of Dermatology, University of Utah, Salt Lake City, UT, USA., O'Toole EA; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.; Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK. |
Abstrakt: |
Competing Interests: Conflicts of interest R.L.M. is an Editorial Trainee with the British Journal of Dermatology and her current position is funded by Palvella Therapeutics to work on a clinical trial, all unrelated to this work (funding paid to the university). A.H. has received research funding from BioCryst Pharmaceuticals, Cure EB, DEBRA France, EBRP, Enzen Therapeutics, Kamari Pharma and Phoenicis Therapeutics, all unrelated to this work (funding paid to INSERM or Imagine). E.A.T. has received research funding from Kamari Pharma and Unilever; has participated in consultancy for Azitra, Palvella Therapeutics and Kamari Pharma; and has been a speaker for Almirall, all unrelated to this work (funding paid to the university). |